患者个人资料对CDK4/6抑制剂治疗结果的影响:现实世界的数据分析
Ioana-Miruna Stanciu1,2, Maria-Cristina Orlov-Slavu1,3, Andreea-Ioana Parosanu1,2
1Department of Oncology, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
International journal of molecular sciences
|April 17, 2025
概括
循环素依赖性激酶4和6 (CDK4/6) 抑制剂改善了转移性HR+/HER2-乳腺癌的结果. 治疗的有效性因患者年龄和瘤生物学而异,需要个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 遗传学 遗传学 是一个
背景情况:
- 循环素依赖性激酶4和6 (CDK4/6) 抑制剂在治疗激素受体阳性 (HR+) /HER2阴性 (HER2-) 转移性乳腺癌方面取得了重大进展.
- 治疗疗效因患者的人口统计学,瘤特征和治疗毒性而受到调节,这强调了需要个性化方法的需要.
研究的目的:
- 研究人口,临床和瘤相关因素对转移性HR+/HER2-乳腺癌中CDK4/6抑制剂的疗效的影响.
- 为了比较不同患者亚组中不同CDK4/6抑制剂 (ribociclib,palbociclib,abemaciclib) 的结果.
主要方法:
- 对95名转移ER阳性,HER2阴性乳腺癌患者进行了回顾性队列研究,这些患者接受了CDK4/6抑制剂和内分泌治疗.
- 与患者年龄,瘤标志物 (Ki67,等级) 和并发症相关的无进展生存 (PFS),总生存 (OS) 和治疗时间 (TOT) 的分析.
主要成果:
- 年轻的患者 (<50岁) 呈现出更具侵略性的瘤 (较高的Ki67级) 和较差的生存结果.
- 利博西克利布表现出最高的生存益处,特别是在年轻患者中.
- 老年患者 (>50岁) 有更多的并发症和毒性;剂量减少与改善的生存率有关.
结论:
- 患者年龄,并发症和瘤生物学是CDK4/6抑制剂疗效的关键决定因素.
- 个性化治疗策略是必不可少的,ribociclib在年轻,更健康的患者中显示出希望,palbociclib作为伴随疾病的老年患者的选择.
相关概念视频
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Cancer Survival Analysis
300
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
300
M-Cdk Drives Transition Into Mitosis
5.4K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.4K
Kaplan-Meier Approach
55
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
55
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K


